ClinicalTrials.gg
Not yet recruitingNCT06835777Updated Feb 19, 2025

Neurophysiological Mechanisms of Placebo and Nocebo Effects in Sports - a Protocol Paper

An interventional study of Positive Expectation and Negative Expectation in Placebo Effect and Nocebo Effect, sponsored by Canterbury Christ Church University. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Canterbury Christ Church University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial aims to investigate the neurophysiological mechanisms of placebo and nocebo effects on sports performance, using Electroencephalography (EEG) and isometric strength testing of the lower extremities.

The primary objective of this trial is to identify temporal mechanisms and cortical regions and networks involved in generating placebo and nocebo effects before (expectation) and at onset of athletic performance (perception).

The trial will include four groups, two of them experimental, one an active control and one natural history, meaning participants in this group will receive no intervention and won't be EEG controlled. Data will be collected on two occasions with baseline data for EEG, expectations and performance as well as key participant characteristics being collected on day one. On day two, in a deceptive process, participants in the two experimental groups will take an inert substance presented as either performance enhancing or inhibiting and subsequently experience a reinforcement of beliefs via exposure to explicit adjectives. EEG data will be collected during reinforcement of beliefs. In the active control group, participants will receive no substance, but this group will follow the same procedure as the experimental groups with neutral adjectives. Participants will then perform isometric strength and fatigue resistance tests on an isometric dynamometer. EEG data as well as subjective data on expectations and rating of perceived exhaustion will be collected.

Read the detailed description

This trial will examine temporal and spatial aspects of neurophysiological mechanisms behind nocebo and placebo effects before (expectation) and at exercise onset (perception) using high-density EEG. It will further investigate possible predictors of responsiveness and non-responsiveness to acute placebo and nocebo stimuli in the context of sports, notably interpretating psychological mechanisms (e.g. personality, beliefs, expectations) as well as temporal neurophysiological measures.

This study is designed as a randomized, controlled clinical trial (RCT) with data collection on two different occasions and four parallel groups: 1) positive-expectations, 2) negative-expectations, 3) control, and 4) natural history.

The first three groups will be addressed as intervention groups. On the first visit, participants' baseline data, specifically performance measures (all groups) and EEG data (all but natural history), as well as key characteristics will be collected. On the second visit, in the belief groups, participants will receive an in-person manipulation of beliefs and two placebo pills and will be informed that they are expected to positively (positive-expectations) or negatively (negative-expectations) affect their isometric strength and fatigue resistance measured using a Biodex System 4 Isokinetic Dynamometer in a 5x5sec test protocol with a minimum of 1 minute rest in between sets. In addition, after a resting period of three minutes, they will perform an isometric knee extension hold to failure at 60% MVC. The control group and the natural history group will receive no pills, with the control group receiving a neutral explanation of EEG data, its relevance and general information about isometric strength testing and the natural history group not receiving EEG at all, but serving as a control to the potential influence of experiencing an EEG set up on performance measures. The primary endpoints of this trial are placebo and nocebo induced changes in EEG signaling via Event Related Potentials (ERPs) during administration of reinforcements of beliefs through words as well as during expectancy and perception phases of physical performance.

The key question of this trial is whether participants exposed to placebo or nocebo stimuli will exhibit distinct neural activity pattern (temporal and spatial) in the context of sports performance. The second major question is, whether individual differences in character traits and states as well as motivation and beliefs can significantly predict the magnitude or likeliness of placebo and nocebo responses in participants' performance in an isometric strength and fatigue resistance task. In addition, EEG data to better understand the valence of and emotional response to words will be used to further investigate how semantics and our choice of words influence susceptibility to placebo and nocebo effects in other people. Several elements that were not adequately addressed in previous studies will be incorporated into this RCT:

(1) temporal and spatial aspects of neural correlates of placebo and nocebo effects in sports, (2) hard data (EEG) on how an individual reacts to semantic implications on performance and (3) correlation of subjective ratings of expectations of performance and data from neural processes associated with affective processing, emotional valence and motivation (LPP,LPC) and anticipation as well as motor preparation (CNV). To further understand the above point may result in a change on how athletes, coaches and therapists approach placebo and nocebo effects in the context of sports performance.

02

Conditions studied

  • Placebo Effect
  • Nocebo Effect

Keywords

  • EEG
  • Placebo
  • Nocebo
  • Sports Performance
03

In context

Lead sponsor

Canterbury Christ Church University is the lead sponsor of 27 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy adult participants (18+)
  • physically active (WHO, 2020)
  • no medical history pf psychological disorders/mental health issues
  • no acute or regular medication intake
  • no severe injury to the lower limb within the last 6 months
  • proficient in english
  • normal or corrected eyesight
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    positive-expectations

    The positive-expectations intervention will consist of two inert pills filled with cornstarch and a manipulation of beliefs regarding the given substance and it's effects. Participants will be informed that the inert pills are neurostimulants, usually used in the context of depression and other mental health issues and that they can positively affect sports performance. Participants will be reinforced about these effects throughout testing via implicit adjectives regarding potential sensations they might experience after pill intake. Reinforcement of beliefs and subsequent strength testing will be EEG controlled.

    Combination Product: Positive Expectation

  • Experimental
    negative-expectations

    The negative-expectations intervention will consist of two inert pills filled with cornstarch and a manipulation of beliefs regarding the given substance and it's effects. Participants will be informed that the inert pills are neuro-depressants, which relieve anxiety and can negatively affect sports performance. Participants will be reinforced about these effects throughout testing via implicit adjectives regarding potential sensations they might experience after pill intake. Reinforcement of beliefs and subsequent strength testing on day two will be EEG controlled.

    Combination Product: Negative Expectation

  • Active comparator
    control

    The control intervention consists of the same testing procedure as the other intervention groups, but no pills or manipulation of beliefs will be administered. Participants will be given a neutral presentation on the testing procedure of the isometric strength testing. Neutral adjectives will be presented instead of a reinforcement of beliefs. Presentation of adjectives and subsequent strength testing will be EEG controlled.

    Other: Control

  • No intervention
    natural history

    Participants will neither receive an EEG nor any sort of intervention. They will do the isometric strength testing on two different occasions like the other groups and will not receive any sort of manipulation of beliefs.

Interventions

  • Combination productPositive Expectation

    The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance enhancing neurostimulant,. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance enhancing qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.

  • Combination productNegative Expectation

    The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance inhibiting neuro-depressant. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance inhibiting qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.

  • OtherControl

    The lead researcher will deliver a short presentation (8 minutes) to participants informing them about EEG research and set ups and give general information about isometric strength testing. They will be shown neutral adjectives unrelated to performance instead of implicit adjectives related to performance (experimental groups). EEG set up and strength testing remains the same as the experimental groups.

06

What researchers measure

Primary outcomes

  1. EEG data - performance

    Temporal neurophysiological data measured by EEG. The Continuous Negative Variation (CNV), an Event Related Potential (ERP), will be used to differentiate positive and negative expectations as well as motor preparation before and at onset of isometric strength testing.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  2. EEG data - reinforcement of beliefs

    Event related potentials (ERP) will be investigated during the reinforcement of beliefs, specifically the late positive potential (LPP) and the late positive component (LPC).

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  3. EEG, exploratory source analysis

    In addition to ERP data, Low-Resolution Electromagnetic Tomography (LORETA) will be used in an exploratory approach to identify specific neural origins associated with placebo and nocebo responses.

    Time frame: From collection of baseline data on day one to the end of day two of data collection

Secondary outcomes

  1. Performance Output, Isometric Forces

    Peak Isometric Force: Measured in Newton-meters (Nm) as the maximum force output during a 5-second unilateral knee extension contraction. Average Isometric Force: Calculated as the mean force output in Nm maintained over a 5-second unilateral knee extension contraction. Isometric Force output data will be analysed in a within and between analysis, the latter being normalized to body mass (Nm/kg).

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  2. Performance Output, Force Consistency

    Force Consistency: Assessed by comparing peak and average force outputs in Nm across five consecutive trials of 5-second contractions.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  3. Performance Output, Endurance Hold and Fatigue Resistance

    Fatigue Resistance and Endurance Hold: Evaluating the time to failure at the 60% maximally voluntary contraction (MVC) hold.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  4. Performance Output, Recovery Capacity

    Recovery Capacity: Determined by examining the ability to maintain force output in Nm across trials with 1-minute rest intervals between contractions.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  5. Heartrate

    Heartrate (bpm) will be collected during and before physical performance as well as during EEG data collection.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  6. Rate of Perceived Exertion (RPE)

    Rate of perceived exertion (RPE) will be used to assess subjective effort and closeness to failure after isometric strength testing

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  7. Electromyographic (EMG) Data

    EMG data of the M. vastus lateralis of the dominant leg during isometric performance tests will be collected.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

Other outcomes

  1. Questionnaires - Anxiety

    Further outcomes measures include questionnaires and inventories to assess key personality traits and states, motivation and beliefs. 1. Cognitive and Somatic State Anxiety levels measured by the Competitive Sport Anxiety Inventory-2 (CSAI-2).

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  2. Questionnaires - Motivation and Perception of Ability

    A 7-point Likert scale will be used to assess the participants' achievement motivation and their approach to performance.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  3. Questionnaires - Optimism

    We will use the Life Orientation Test-Revised (LOT-R) to test for the level of optimism versus pessimism.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  4. Questionnaires - Sport supplement use and belief

    We will collect data on participants' use of and beliefs on sport supplements.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  5. Questionnaires - Resilience

    Participants' beliefs about their own general resilience will be assessed using the Resilience Evaluation Scale (RES).

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  6. Questionnaires - Sensitivity

    We will assess participants' sensitivity to internal bodily sensations using the Body Vigilance Scale (BVS).

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  7. Questionnaires - Emotions

    Positive and negative affects will be measured before data collection and after pill administration using a modified version of the Positive and Negative Affect Schedule (PANAS) using the subscales investigating negative affect, positive affect, fear, self-assurance, attentiveness and fatigue.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

  8. Questionnaires - Expectations of performance

    We will assess pre- and post-intervention expectancy/perception levels of performance as well as the participants' expectancies and perceptions of substance effect before and after data collection using a 10 point Visual Analogue Scale (VAS) and 7 point Likert scale respectively.

    Time frame: From collection of baseline data on day one to the end of day two of data collection.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Dec 2025, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 19, 2025
StartEst.
Mar 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06835777
Lead sponsor
Canterbury Christ Church University
Responsible party
Janina Hanssen (PhD Candidate, Canterbury Christ Church University) — Principal investigator
First posted
Feb 19, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 19, 2025

Study contacts

Janina Hanssen, M.Sc.
Contact
JH1718@canterbruy.ac.uk
07553606641

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion